BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

J&J buying Alios for $1.75B

Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV). more >>

   COMPANY NEWS

Pfizer, Kyowa partner on cancer combo trial

Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will co-fund a Phase Ib trial of Pfizer's PF-05082566 plus Kyowa's Poteligeo mogamulizumab to treat solid tumors. Pfizer will run the U.S. trial, which is expected to start next year. more >>

MacroGenics, Takeda announce second DART deal

MacroGenics Inc. (NASDAQ:MGNX) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) an option to license exclusive, worldwide rights to four programs against undisclosed jointly selected targets. The products will be developed using MacroGenics' Dual-Affinity Re-Targeting (DART) technology. more >>

   FINANCIAL NEWS

Ebola plays up after Texas diagnosis

Post-market traders bid up prices of Ebola plays after the CDC and the Texas Department of State Health Services said a patient in a Texas hospital has been diagnosed with the infection. The agencies said the diagnosis is the first in the U.S. more >>

Stem cell play ReproCell creates VC fund

ReproCell Inc. (JASDAQ:4978) and Shinsei Bank, a subsidiary of Shinsei Corporate Investment Ltd., raised Y800 million ($7.28 million) for Cell Innovation Partners LP. more >>

   POLITICS & POLICY

FDA starts clock on LDT regulation

On Tuesday, FDA released two draft guidance documents that outline the agency's plans for regulating laboratory-developed tests (LDTs). The draft guidance is largely in line with documents pre-released in July (see BioCentury, August 11). more >>

CMS says payments database is "first wave"

CMS released what it called its "first wave" of its Open Payments database, which details consulting fees, research grants, travel reimbursements, and "other" gifts healthcare companies provided to physicians and teaching hospitals during the last five months of 2013. more >>

NIAID funds development of new vaccine adjuvants

NIH's National Institute of Allergy and Infectious Diseases awarded five-year contracts to seven research institutions developing new vaccine adjuvants that boost responses by activating the adaptive immune system. The agency said total funding for all seven contracts could reach $70 million. more >>

NIH awards $46M in BRAIN initiative grants

NIH issued $46 million in grants to support 58 research projects that are part of the Brain Research through Application of Innovative Neurotechnologies (BRAIN) initiative. Most of the grants are for new neuroscience tools and techniques, such as using lasers to guide nerve cell firing and stimulating circuits with radio waves. more >>

Advertisement

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS
COVER STORY

Patching compassionate access

Congress is gearing up to reconsider compassionate access to drugs, but wholesale reform looks unlikely.

Targeting PREA

Oncologists and patient advocates want Pediatric Research Equity Act mandates to study new targeted cancer drugs in children.

PRODUCT DISCOVERY & DEVELOPMENT

An arresting development

G1 Therapeutics aims for first-in-class chemoprotectant with CDK4 and CDK6 inhibitor.

EMERGING COMPANY PROFILE

Ossianix: Shark teeth

Ossianix is developing small shark-derived single domain antibodies that could hit targets tough to access with traditional approaches.

Oricula: Preserving hearing

Oricula is developing a small molecule that could prevent hearing loss during aminoglycoside treatment.

REGULATION

Patient factors

A dearth of programs for blood disorder patients with inhibitors will leave a major unmet need until gene therapies come to market.

FINANCE

Adopting Adaptimmune

Why investors preferred Adaptimmune's TCR platform to other T cell therapy cos

CureVac bet paying off

Boehringer cancer vaccine deal shows Hopp's EUR80 million CureVac bet paying off

Avalon-GSK bet on familiarity, speed

How Avalon, GSK chose next newcos for their pre-POC collaboration

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement